舌下减敏疗法治疗花粉全身性成效高

纽约（华尔街日报健康信报）12月21日电—据《变态反应，结核病及分子生物学月报》周报11月刊一篇报道，舌下减敏制剂（SLIT）外科手术雄花诱发的呼吸道过敏能力也高。“利用SLIT提高溃疡的肺炎及药物折扣，增加社会经济负担，”威尼斯Genoa大学Giovanni Passalacqua教授感叹。“先前已经有加速口服制剂增加社会负担，但这是首次对实用制剂（SLIT）透过严格评量的结果。”Passalacqua教授及其同事们对雄花诱发的过敏病态溃疡和结核病治果透过研究，评量利用SLIT结合新标准外科手术及另行利用新标准外科手术的服务费及。研究技术人员报道，SLIT使63.1%的病征疼痛优化，并预防病态51.8%的病征出现结核病，而另行技术的发展新标准制剂意味着使23.2%的病征疼痛优化，预防病态28.9%的病征出现结核病。而且同新标准外科手术相对，SLIT的并不需要及间接费时均增加：SLIT病征外科手术的总体费时最低国家所公共服务系统预测的4年中另行药物外科手术费时，并且最低社会公众预测的2年中另行药物外科手术费时。“SLIT并不用算是加速口服制剂的即使如此，” Passalacqua教授解释感叹，“而是将其作为外科手术方法的另一选择。它最大的优点在于其最优的安全病态和病征的易接受病态。”“SLIT在美国没有在此之前技术的发展，尽管一些变态反应专家技术的发展它（并且赢取了满意的结果），” Passalacqua教授感叹。“中欧具体情况基本上不同，SLIT在很多国家所中广泛技术的发展（如威尼斯，法国，法国，西班牙，西班牙，希腊及匈牙利）。”当前的问题是SLIT没有得到FDA的批准，“Passalacqua教授补充道。“受到FDA拥护的临床研究正在透过中，并再一得到批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma & Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

撰稿人：紫色梦境